News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NanoViricides, Inc. (NNVC.PK) Signs Agreement With Viroclinics Biosciences BV For Testing Of Various Nanoviricides Against Specific Viruses Of Current Concern



2/4/2014 9:07:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WEST HAVEN, Conn.--(BUSINESS WIRE)--Tuesday, February 4th, 2014 - NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) reported today that it has signed a “confidential disclosure agreement” (“CDA”) with Viroclinics Biosciences, BV (“Viroclinics”), a spinoff of the Department of Viroscience at the Erasmus Medical Centre (“Erasmus”) in Rotterdam, the Netherlands. The agreement will allow the scientists at Viroclinics to develop a specific proposal for the testing of different nanoviricides® , such as FluCide™, against viruses of mutual interest to both organizations.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES